Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097707 · ClinicalTrials.gov registry record · Phase 2
A Study in Men With Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 414
- Enrollment target
NCT01097707: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT01097707 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 414 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (211% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01097707, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 414 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
Primary Outcome
IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) with an IPSS Total Score range of 0-35 points. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Interventions
- DRUG Placebo
- DRUG LY500307
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Why NCT01097707 stopped before completion
NCT01097707 is an interventional study that assigns participants to a tested intervention. The registered 414 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (211% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01097707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01097707 about?
NCT01097707 is a clinical study titled "A Study in Men With Benign Prostatic Hyperplasia". The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
What is the current status of trial NCT01097707?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 414 participants. The study started on 2010-04. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01097707?
The interventions under investigation include: Placebo (DRUG), LY500307 (DRUG).
Who is sponsoring clinical trial NCT01097707?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01097707's enrollment target sits among peer trials
414 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia